Johnson & Johnson (NYSE:JNJ) : Currently there are 12 street experts covering Johnson & Johnson (NYSE:JNJ) stock. The most bullish and bearish price target for the stock is $125 and $93 respectively for the short term. The average price target of all the analysts comes to $116.17. The estimated standard deviation from the target is $9.61.
Shares of Johnson & Johnson rose by 3.34% in the last five trading days and 7.55% for the last 4 weeks. Johnson & Johnson is up 11.88% in the last 3-month period. Year-to-Date the stock performance stands at 19.79%.
Johnson & Johnson (NYSE:JNJ) has an average broker rating of 2.22, which is interpreted as a Buy, as rated by 18 equity analysts. Nonetheless, 7 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 8 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.
Johnson & Johnson (NYSE:JNJ): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $119.18 and $119.16 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $121.41. The buying momentum continued till the end and the stock did not give up its gains. It closed at $121.30, notching a gain of 1.65% for the day. The total traded volume was 11,559,922 . The stock had closed at $119.33 on the previous day.
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.